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Abstract
Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model
was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV
protease inhibitor, telaprevir. Variant fitness was estimated using a model in which variants were selected by competition
for shared limited replication space. Fitness was represented in the absence of telaprevir by different variant production rate
constants and in the presence of telaprevir by additional antiviral blockage by telaprevir. Model parameters, including rate
constants for viral production, clearance, and effective telaprevir concentration, were estimated from 1) plasma HCV RNA
levels of subjects before, during, and after dosing, 2) post-dosing prevalence of plasma variants from subjects, and 3)
sensitivity of variants to telaprevir in the HCV replicon. The model provided a good fit to plasma HCV RNA levels observed
both during and after telaprevir dosing, as well as to variant prevalence observed after telaprevir dosing. After an initial
sharp decline in HCV RNA levels during dosing with telaprevir, HCV RNA levels increased in some subjects. The model
predicted this increase to be caused by pre-existing variants with sufficient fitness to expand once available replication
space increased due to rapid clearance of wild-type (WT) virus. The average replicative fitness estimates in the absence of
telaprevir ranged from 1% to 68% of WT fitness. Compared to the relative fitness method, the in vivo estimates from the
viral dynamic model corresponded more closely to in vitro replicon data, as well as to qualitative behaviors observed in both
on-dosing and long-term post-dosing clinical data. The modeling fitness estimates were robust in sensitivity analyses in
which the restoration dynamics of replication space and assumptions of HCV mutation rates were varied.
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Introduction
Hepatitis C virus (HCV) is estimated to infect 170 million
people worldwide [1]. Current HCV treatment with pegylated
interferon (Peg-IFN) and ribavirin (RBV) for the most common
genotype 1 strain requires 48 weeks and only 42% to 50% of
patients naı ¨ve from treatment achieve sustained viral response
(SVR) [2,3]. Several specifically-targeted antiviral therapies for
HCV (STAT-C) are under development [4]. Telaprevir (also
known as VX-950), is a STAT-C that targets the HCV NS3N4A
protease and has demonstrated antiviral activity in an HCV
replicon assay [5] and in clinical trials [6,7].
Previously published models of HCV viral dynamics in subjects
treated with interferon (IFN), Peg-IFN and RBV have assumed the
HCV population within a subject to be relatively homogeneous
with respect to sensitivity to these antiviral agents [8,9,10,11].
However, as a consequence of its high replication rate and error-
prone polymerase, HCV exists as a quasispecies. In fact, recent
data from clinical trials evaluating HCV protease inhibitors have
revealed the presence of viral variants with varying levels of
sensitivity to these agents [12,13,14,15]. Viral variants have also
been detected at levels around 10
23 of wild-type NS3N4A HCV
(WT) level prior to dosing in treatment-naı ¨ve subjects [12,13].
Upon exposure to protease inhibitors, the composition of the
HCV quasispecies was altered, as revealed by sequencing of
plasma HCV RNA and isolated viral clones obtained from
subjects dosed with telaprevir [14,15] and boceprevir [13]. These
variants have also been reported to exhibit reduced fitness [16,17]
and reduced susceptibility to other protease inhibitors in vitro [18].
Models of viral dynamics and emergence of resistance have been
developed for viruses like HIV that exhibit a high degree of genetic
variability and are capable of establishing chronic infections
[19,20,21]. In these models, variants were assigned different
replicative rates, based either on their infection rate constants,
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parameterized using on-treatment HIV RNA levels and CD4+
counts for a small number of resistant variants; however, many of the
models did not include sufficient data, in particular the prevalence of
variants, to allow estimation of model parameters with good
precision. Here, a multi-variant model was developed to represent
HCV viral dynamics in subjects dosed with telaprevir monotherapy,
to estimate the fitness of variants resistant to telaprevir, and to
investigate the importance of replication space dynamics, mutations
during treatment, and pre-existing variants on the overall response.
Methods
Ethics statement
The study protocol and informed consent form (ICF) were
reviewed and approved by an Independent Ethics Committee
(IEC) at each of the 3 study centers before initiation of the study.
The sites are: Pharma Bio-Research Group BV Medisch Ethische
Toetsings Commissie METC Stichting Beoordeling Ethiek Bio-
Medisch Onnderzoek P.O. Box 1004 9400 BA Assen, Amsterdam
Medical Center Medisch Ethische Toetsings Commissie METC
Stichting Beoordeling Ethiek Bio-Medisch Onderzoek P.O. Box
1004 9400 BA ASSEN, The Netherlands Medisch Ethics
Toetsings Commissie Meibergdreef 9 P.O. Box 22660 NL 1100
DD Amsterdam, Saarland University Hospital A ¨rztekammer des
Saarlandes Ethikkommission Faktoreistrabe 4 66111 Saarbru ¨cken
Germany. Written informed consent was obtained in accordance
with the Declaration of Helsinski.
Subject population and study design
Thirty-four subjects with HCV genotype 1 were enrolled in Study
VX04-950-101, a randomized, double-blind, placebo-controlled, 14-
day, multi-dose, Phase 1b trial. Subjects received placebo (n=6) or
one of the following dosages of telaprevir administered as a
suspension: 450 mg every 8 hours (n=10), 750 mg every 8 hours
(n=8), or 1250 mg every 12 hours (n=10). Subjects’ baseline
characteristics are provided in Supplementary Table S1. Variants
were detected using clonal sequencing (details provided in [14]). For
the model parameterization described here, data from 26 of the 28
subjects dosed with telaprevir were used. No variants weredetected in
one subject, and therefore this subject was excluded from further
analysis. Estimation results in another subject with 8 variants did not
converge to a global optimum---a standard requirement for
computationally rigorous estimation; this subject was also excluded.
For each subject, we examined only variants identified by clonal
sequencing that were present either at $5% of the HCV
population at 2 measurement points or $10% of the HCV
population at 1 time point (5% is the detection limit of the clonal
sequencing measurement performed here). The number of
variants per subject ranged from 2 to 6; the number of variants
for each subject is provided in Supplementary Table S2. These
clonal sequencing results identified amino acid differences in HCV
NS3N4A that correlated with changes in telaprevir resistance in
vitro. A larger network representation of quasispecies containing an
even greater number of variants could have provided a more
complete picture, but was not examined here because no in-
subject kinetic data were available to estimate their fitness, and/or
no in vitro data were available on their resistance to telaprevir.
A multi-variant viral dynamic model and simulation
The basic evolutionary dynamic among HCV resistant variants
in subjects dosed with telaprevir follows Equations 1–5, with
variable and parameter descriptions provided in Table 1.
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Variant Vi represents a virion with characterized amino-acid
substitution(s) and in vitro defined telaprevir sensitivity. Variant Vi
infects target cells T to form variant-i-infected cells Ii at rate bTVi.
It is assumed that each infected cell Ii is infected by only one
variant, and each variant competes for the same target cells T. The
assumed single-variant infection is consistent with the fact that
recombination in HCV appears rarely [22]. Target cells T also
represent limited replication ‘‘space’’ shared by all variants. Target
cells T ranges from their baseline level T0 to their maximum level
Tmax. Each infected cell Ii produces a population of variants at
production rate pfi, with fraction mi,j mutating to produce variant j.
The mi,i were normalized to follow mi,i + gj,j? i mi,j=1.
Different production rate constants pfi, but the same infection rate
constants (b) and clearance rate constants (c) are assumed for different
variants. The assumption of different production pfi is consistent with
the function of the NS3N4A protease in cleaving a precursor
polyprotein [23], and with variants having been observed with
Author Summary
Hepatitis C virus (HCV) infects an estimated 170 million
people worldwide. Current treatment for HCV is 48 weeks
of peginterferon and ribavirin of which patient response
has large variability. Recently, specifically targeted antiviral
therapies for HCV (STAT-C) are under clinical development
and have shown potentials to improve response. Within a
patient, HCV exists as quasispecies consisting of multiple
variants. Models of HCV dynamics in response to
peginterferon and ribavirin treatment have been proposed
elsewhere, with HCV quasispecies assumed to respond
homogenously to treatment. However, some of the HCV
variants possess different degrees of sensitivity to a STAT-C
compound, and therefore, selections and competitions
among variants have been observed in patients treated
with STAT-C. We have developed a viral dynamic model
that quantifies the evolution of multiple variants in
patients dosed in monotherapy with telaprevir, a com-
pound specifically designed to inhibit HCV NS3.4A
protease. Our novel modeling approach integrated data
from both in vitro and in patients, both during and after
dosing with telaprevir. Our model quantified the antiviral
response to telaprevir and the in vivo fitness of variants.
The model provides a useful framework for the designs of
STAT-C during clinical development and for understanding
the consequences of failure to STAT-C.
A model of HCV Evolution on Protease Inhibitor
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rate ratio fi quantifies variant i replication disadvantage in the absence
of telaprevir. In the presence of telaprevir, the viral production was
further reduced by a factor (1- ei). The assumed same infection b is
consistent with lack of interference between HCV protease and HCV
envelope proteins. The assumed same plasma clearance c is consistent
with the data in interferon-based and telaprevir-based treatments [24].
Despite large differences in the antiviral blockages between both
treatment groups, similar cvalues were observed. This suggests that cis
independent of antiviral blockage and therefore, may have the same
value among variants. Alternative model formulations with different
variants fitness assigned to infection rates or to plasma virion clearance
rates produced similar dynamics (Supplementary Figure S3).
Antiviral activities of telaprevir were implemented by assuming a
dual role. Telaprevir blocks the production of HCV by inhibiting the
activity of the NS3N4A protease with blockage factors ei calculated
using Equation 4. The blockage factors for all variants within a
subject were calculated using a single effective telaprevir concentra-
tion [TVR], with its value estimated from the HCV RNA, variant
prevalence dynamics within each subject, and in vitro susceptibility of
variants to telaprevir. The susceptibility factor IC50,i and Hill
coefficient hi were estimated from in vitro susceptibility of variant i
to telaprevir [16,17] and were provided in Supplementary Table S3.
The second roleof telaprevir is to enhance infected cellclearance d,a
parameter contributing to the second-phase decline. WT dWT values
were up to 10-times higher in subjects dosed with telaprevir than in
subjects treated with Peg-IFN/RBV [24]; only a 0.2-fold increase in
the second-phase decline is explained by increased telaprevir
blockage alone (detail calculations are provided in the Supplementary
Text S1). On the other hand, in the limit when a subject is not dosed
with telaprevir, di should converge to the clearance without drugs
dnodrug. These observations were incorporated into the model by
assuming that di increased proportionally to the logarithmic of
blockage factor (1-ei), given in Equation 5. We also examined
alternative models to Equation 5, given by Equations 6 or 7.
di~dnodrugzddrug 1{ei ðÞ Vi ð6Þ
di~ dnodrugzddrug if telaprevir is present Vi
dnodrug if telaprevir is absent
ð7Þ
Prior to dosing, the differential equations wereinitialized at steady-
state. The steady-state initialization is consistent with years of chronic
HCV infection. This steady-state solution was used to predict the pre-
dosing variant prevalence. During dosing with telaprevir, replication
rates of WT and variants were reduced by factors proportional to
their sensitivity to telaprevir (blockage factors). Following completion
of telaprevir dosing, these blockages were removed. Consequently,
the WT and variants present would compete for available replication
space with competitive advantages governed by fitness of WT and
variants in the absence of any drug.
The majority of the results were reported with replication space
T described by Equation 1. We also examined another
representation of T given by Equation 8 [10]. The values of T0
and I0,i were fixed prior to estimation to the steady-state values of
T and Ii obtained from models with Equation 1. To obtain a
similar rate of T increase, the regeneration rate c were related to
parameters in Equation 1 by c=s/(T0+gi I0,i).
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Calculation of mutation rates
Previously reported HCV mutation rates range from 1.5610
23
nucleotide changes/site/y [25] to 5610
23 nucleotide changes/
site/y [26]. These values were converted to per nucleotide position
per replication cycle by assuming an average duration of the HCV
replication cycle of 9.5 days calculated as (1/c+1/d) with typical
values for c and d assumed to be the same as those from Peg-IFN/
RBV treatments [8,9]. These calculations resulted in a mutation
rate m of 1.2610
24 nucleotide changes/site/cycle. The estima-
tions were repeated for different mutation rates of 1.2610
22,
1.2610
23 and 1.2610
25 nucleotide changes/site/cycle.
The mutation rates were computed prior to each estimation by
assuming a rate of 1.2610
24 per nucleotide position per replication
cycle. The specific mutation rates between two variants were
computed by exponentiating the mutation rate for a single mutation
by the number of nucleotide mutations between these variants. These
rates were genotype specific. For example, to produce NS3N4A
proteasemutationatposition36V36M,genotype1arequiresasingle
nucleotide mutation (from codon GTG to ATG), while genotype 1b
requires two mutations (from GTT to ATG).
Parameter estimation
During-dosing and post-dosing HCV RNA levels and post-dosing
variant prevalence data from the clinical study described above
Table 1. Descriptions of model variables and parameters.
Names Descriptions
(dot above) a
variable
time-derivative of a state variable
T healthy target cells, or replication ‘space’
s target cell synthesis rate
d target cell degradation rate constant
b infection rate constant
Vi or Vj plasma virion ‘‘i’’ or ‘‘j’’ with characterized
amino-acid substitution(s) and different
sensitivities to telaprevir in vitro
Ii Vi-infected cells
p production rate constant of wild-type (WT)
mj,i mutation rates from Vj to Vi
fi ratio of production rates of a variant to WT
c plasma virion clearance rate constant
ei production blockage factor of
telaprevir to variant i
[TVR] effective telaprevir concentration for the observed
inhibitions to WT and variants, deduced from the
sensitivity curve measured in replicon cells
IC50,i IC50 of variant i to telaprevir as
measured in replicon cells
hi Hill coefficient of exponentiation to
represent the inhibition curve of variants
by telaprevir as measured in replicon cells
d0 infected-cell clearance rate constant
in subjects dosed with pegIFN and RBV
d1 additional infected-cell clearance rate
constant in subjects dosed with telaprevir
doi:10.1371/journal.pcbi.1000745.t001
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model parameters. This simultaneous estimation allowed fitness
estimation in subjects with HCV RNA levels below the clonal
sequencing detection limit (100 IU/mL) at the end of telaprevir
dosing but with detectable HCV RNA within a week after
completion of dosing. The estimation minimized the maximum
likelihood objective function. Parameters estimated for each subject
included c, d1, p, fi,a n d[TVR]. Parameter bounds are provided in
Supplementary Table S4. Fitness parameter fi was estimated for each
variant; the number of assessed variants for each subject varies
between2to6(SupplementaryTableS2).Theremainingparameters
were pre-computed prior to estimation runs, including mi,j,
b=0.05h
21,a n ddnodrug=0.12d
21, assuming that the clearance
without drugs dnodrug is the same as the clearance on Peg-IFN/RBV
treatment. Because we do not have direct measurement of target cells
nor productively infected cells, we were able to estimate only the
overall viral replication rates, or the basic reproductive ratio R0,WT=
pbTmax/(cd). If measurements of infected cells and target cells were
available, parameters p, b, s,a n dd may be adjusted to match the
measured infected and target cells while maintaining the constraint
that R0,WTremainsconstant. For a given R0,WTvalue,somedegreeof
freedoms exist in choosing p, b, s,a n dd, while clearance parameters c
and d would be constrained by the decline kinetics. Numerically, this
is implemented by fixing parameters b and the s/d ratio, and
normalized HCV RNA levels to the baseline value similar to the
implementation in [19]. In the base run, we chose b=0.05h
21 and
Tmax= s/d=10, and obtained R0,WT from estimates of p.T h e s e
choices of band Tmaxprior to estimation did not change the estimates
of other parameters estimated from these data, including clearance
rates c, d, R0,WT, and fitness fi. For example, re-estimation with
different b values, shown in Supplementary Figure S2, resulted in
similar fitness and R0,WT values. The results also demonstrated an
inverse relationship between estimated p and assumed b, supporting
t h ef a c tt h a tw ew e r eo n l ya b l et oe s t i m a t eR0,WT, but not p nor b
individually. The breakdown of replication parameters constituting
R0,WT (p, b and Tmax) may be refined in future studies when direct
measurements of target and infected cells become available.
Susceptibility factors IC50,i and hi, were fixed during each estimation.
The robustnessof the estimates as a function of the dynamicsof target
cellsTsynthesisrateswasalsoexaminedbycomparingthecasewhen
s was estimated to the case when s was fixed to 1 h
21.
Comparison to relative fitness method
In addition to the modeling approach described in details, we also
computedrelativefitness(RF).Foravariantiat twoconsecutive times
t1 and t2 with with viral loads V
i
t1 and V
i
t2,t h eR Fw a sc o m p u t e d
from data from the equation below. If the prevalence was below the
detection limit, the value was assumed to be at the limit (5% in this
study). Model-derived RF was computed similarly, except that rather
than evaluating viral load changes at two consecutive times, the
change was evaluated at a specified time t using time-derivatives.
RF
i,WT
ti,t2 ðÞ ~
log Vi
t2
  
{log Vi
t1
  
log VWT
t2
  
{log VWT
t1
  
Model{derived RF
i,WT
t ðÞ ~
d
dt
log Vi
t
     
d
dt
log VWT
t
     
Numerical implementation
The simulations were implemented by normalizing the plasma
virion value with the baseline values obtained after solving the
steady-state initial condition. The clearance and replication rates,
the balance of which is implicit in the baseline viral load, were
estimated directly from HCV RNA decline (during dosing) and
rebound (after dosing). The simulation and estimation were
implemented using Jacobian Software (R) (RES Group Inc.), using
methods described in [27,28,29,30,31]. Additional information is
provided in Supplementary Text S1.
Results
Correspondence between data and model-fit
A parameterized multi-variant viral dynamic model was
developed to represent the antiviral responses of subjects to
telaprevir and to estimate the fitness of variants resistant to
telaprevir. Descriptions and schematic of the model is shown in
Figure 1. The list of major variants and the nucleotide distances
between them are shown in Figure 1a. A schematic of the model is
shown in Figure 1b and described by Equations 1–5. Replicative
fitness of variants was represented by their different production
rate constants pfi. The basic reproductive ratio of WT HCV R0,WT,
relative fitness fi, and clearances c, d were estimated from time
series of both plasma HCV RNA and variant prevalences, with
details provided in the Methods section.
The results of the best-fit model corresponded well with
observed data. Results in Figure 1c and Figure 1d show an
example of a subject who received 450 mg telaprevir q8h for 2
weeks, and whose plasma HCV RNA levels rebounded on
dosing. The correspondence between data and model for
additional subjects is provided in Supplementary Figure S1.
Assuming a pre-dosing steady-state, the best-fit model predicted
that HCV with WT NS3N4A protease dominated the HCV
quasispecies population as the most fit variant in the absence of
any drug, and variant prevalences were near the levels predicted
from HCV mutation rates. Upon dosing with telaprevir, WT
declined rapidly. Resistant variants also declined initially because
of reduced influx of new mutations from WT and, in variants
with low-level resistance, because of blockage by telaprevir (the
assessment of relative contribution is provided in later section). As
the total viral load declined, available replication space was
predicted to increase. Such an increase, along with sufficient on-
dosing fitness of variants, is necessary for emergence of variants.
Had T remained constant, none of the variants would have
rebounded because each variant would have had a reduced
replication flux due to the reduced number of WT available to
generate the variant. For the subject shown in Figure 1c and
Figure 1d, variants with a single mutation (V36M or R155K) or a
double mutation (V36M/R155K) within their NS3N4A protease
were responsible for the increase in HCV RNA levels detected
initially on Day 6. WT levels were predicted to increase again
around Day 8 because of back mutations from variants. When
telaprevir dosing was stopped, WT, V36M, and R155K variants
out-competed the V36M/R155K variant, and WT eventually
regained dominance of the HCV quasispecies population to
reach a predicted level of $95% of the viral population in 300
days, although V36M persisted for up to 200 days in this subject.
The model predicted that immediately after dosing was stopped,
V36M initially out-competed WT for available replication space
because it was relatively fit and it was 10
4-times more prevalent.
V36M persisted because infected-cell clearance was relatively
slow.
Overall fitness estimates
The estimated fitness obtained from 26 subjects suggests
reduced replicative capacity of all telaprevir-resistant variants
A model of HCV Evolution on Protease Inhibitor
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production rate ratio (f) for all variants, which ranges from 1%
to 68% of WT replication. Estimation errors associated with the
fitness values were reported as the standard deviation of the
estimation error; the errors ranged between 0.03 and 0.12 for
variants detected in $4 patients, and between 0.4 and 3.26 for
variants detected in #2 patients. The estimate errors were large
especially for variants detected in #2 patients that the fitness
estimates must be interpreted with cautions. The variants were
sorted based on their resistance to telaprevir as measured in
replicon cells. The first 7 variants (R155M to A156S) are low-level
resistant variants (defined as variants with IC50 # the mean
estimated effective telaprevir concentration in vivo when telaprevir
is dosed orally at 750 mg q8h). Among all variants, V36M and
R155K single mutant variants with low-level telaprevir resistance
have the highest f values of 0.68 and 0.66, respectively. Among the
high-level resistant variants, the double mutant V36M/R155K
had the highest f of 0.51.
Comparison of the fitness estimates from viral dynamic
modeling and from the Relative Fitness
Previously, we reported fitness estimates based on variants’
growth in a subset of subjects [14], using a method similar to the
relative fitness (RF) approach [32,33], normalized to 0–100 scale.
In contrast to our earlier RF estimates [14], the fitness estimates
herein included data of on-dosing HCV RNA and 3–7 month
clonal sequencing, and was expanded to include more subjects
(n=8 for previous estimates, n=26 for current estimates). The
correspondence between these previously reported in vivo fitness
estimates, the current in vivo fitness estimates presented herein,
and the in vitro fitness estimates reported by others [16,17] are
provided in Figure 2. Figure 2a shows the correspondence of the
current in vivo estimates to the in vitro fitness estimates. With the
exception of estimates for variant V36A (which appeared to be an
outlier in the in vitro estimates), all these fitness estimates were in
good agreement. In contrast, Figure 2b shows correspondence of
our previous in vivo RF estimates [14] with the in vitro estimates:
the in vivo fitness estimates of many of the variants were higher
than those of in vitro fitness. Thus, compared to the RF method,
the fitness estimates presented herein were more consistent with
both clinical data [14] and the fitness estimates as measured in
vitro. For example, current estimates suggest that variant V36M/
R155K is less fit than variant R155K, but RF estimates suggested
otherwise. The reduced fitness of V36M/R155K is consistent
with the data that show increased prevalence at later times (Day
21–23 vs. Day 14; Month 3–7 vs. Day 21–23) of WT, V36M and
R155K as compared to the decreased prevalence of V36M/
R155K.
An example from a subject (Subject 2, Supplementary Figure
S1a and b) demonstrated why fitness estimated from the current
Figure 1. A multi-variant viral dynamic model to quantify response to telaprevir treatment. Panel a, Superset of HCV genotype 1a
variants uncovered in subjects dosed with telaprevir. Each node represents a variant of which the amino acid mutation is printed. Only variants
detected in $5 subjects are shown. Variants were within 2 nucleotide changes from wild-type HCV. Panel b, Schematic of the model. Panels c and
d, correspondence between data and best-fit model for Subject 1. Diamonds, data; solid line, best-fit model; dashed lines, predicted variant
contribution to the overall plasma HCV RNA; circles, HCV RNA levels of variants.
doi:10.1371/journal.pcbi.1000745.g001
A model of HCV Evolution on Protease Inhibitor
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using the RF method [14]. For this subject, the clonal sequencing
data show that although both WT and V36A comprised ,5% of
the population at Day 14, both were detectable at Day 21, with
V36A prevalence relative to that of WT increasing between Days
14 and 21. The current model predicted that at Day 14, when
telaprevir dosing was discontinued, V36A HCV RNA levels were
about 2-log higher than those of WT. Thus, despite the reduced
fitness of V36A over WT, V36A would continue to infect the
majority of the target cells T between Days 14 and 21. However,
by Day 150, WT dominated the quasispecies because of its higher
fitness. If we computed RF of V36A (vs. WT) based only on
prevalence data at Day 14 and 21 (RFD14 vs. D21, V36A vs. WT)
and, assuming the same Day 14 prevalence levels of 5%, then
RFD14 vs. D21, V36A vs. WT =0.337, a value .0 that misleadingly
implies that V36A is more fit than WT. However, this conclusion
is inconsistent with the RF calculated between Day 21 and Day
150 (RFD21 vs. D150, V36A vs. WT)o f20.101, a value ,0 which
implies that WT is more fit than V36A. On the other hand, the
modeling herein estimated fV36A=0.578, and by using the
on-dosing data, correctly accounts for higher V36A levels than
WT levels at Day 14, higher V36A levels at Day 21, and reduced
levels of V36A at Day 150. Based on the current modeling results,
we also can calculate RF values at specific timepoints using a time-
derivative of the HCV RNA levels (model-derived RF, Table 3).
For the V36A variant, the Day 15 model-derived RF was
much higher than the RF at Day 100 (20.671 vs. 0.023),
demonstrating dependency of RF values on the specific
timing of sample collection. This example demonstrates the
advantages of the modeling approach for estimating variants’
fitness.
Likelihood of variants pre-existing prior to dosing
To examine the likelihood of these resistant variants pre-existing
before dosing, the time necessary to generate these variants, if they
did not pre-exist, was estimated. The best-fit model for Subject 1
above was reinitialized with an HCV population consisting only of
WT before dosing started. The results are provided in Figure 3.
Had the HCV population consisted only of WT before dosing, the
predicted HCV RNA rebound on dosing would be delayed
compared to the observed rebound. The poorer (delayed) fit of this
modified simulation compared to the one started with a steady-
state level of variants before dosing further highlights the
likelihood that these variants pre-exist at a steady-state level.
Because most subjects in this study have been infected with HCV
for years, plenty of time was available for the variants to reach
their steady-state levels prior to dosing.
Sensitivity to different replication space dynamics
To understand the contribution of replication space dynamics to
the rebound dynamics of resistant variants, we examined three
cases: 1) target cells T followed Equation 1 with synthesis rate s
estimated, 2) T followed Equation 1 with s fixed to its upper bound
(1 h
21), and 3) T followed Equation 8. For these three cases
applied to Subject 1, all models corresponded well with observed
data (Figure 4), suggesting robustness of the models to these
assumptions of T dynamics. For T dynamics represented by
Equation 1, increasing s implies faster dynamics for target cells to
reach their maximum levels (Tmax), resulting in an earlier HCV
RNA rebounds. The objective values for the first two cases (s
estimated and s fixed) for all subjects are shown in Figure 5a. The
third case was not applied to all subjects because this case has
different underlying equations compared to the first two cases ---
Table 2. Estimates of variants replication rate relative to wild-type HCV (f) and corresponding predictions of their pre-dosing
prevalence.
Variantsa Genotype Nucleotide IC50 Nb Fitness Precision
Predicted pre-dosing
prevalence
changes from WT relative to WT
c
mean (SD) relative
production f
d
median (range) SD of
the estimation error
e mean [lower, upper]
f
R155M 1a 1 5.5 (L) 2 0.01 (n.a.) n.a. 1.2 [n.a, n.a.]N10
24
T54A 1a 1 6.3 (L) 15 0.55 (0.24) 0.10 [0.03-8.62] 2.6 [1.3, 70]N10
24
T54S 1a,1b 1 ND
g (L) 2 0.58 (0.04) 1.11 [1.01-1.21] 2.8 [n.a., n.a.]N10
24
V36M 1a 1 7.0(L) 12 0.68 (0.16) 0.03 [0.01-2.44] 3.7 [2.0, 13]N10
24
R155K 1a 1 7.4(L) 12 0.66 (0.17) 0.04 [0.01-2.79] 3.4 [1.8, 12]N10
24
V36A 1a,1b 1 7.4(L) 21 0.49 (0.21) 0.04 [0.02-7.01] 2.3 [1.4, 10]N10
24
A156S 1b 1 9.6(L) 2 0.17 (0.07) 3.26 [0.09-6.43] 1.4 [1.2, 1.6]N10
24
R155T 1a 1 19.8(H) 4 0.22 (0.13) 0.06 [0.01-0.08] 1.5 [n.a., n.a.]N10
24
V36M/R155K 1a 2 <62(H) 9 0.51 (0.14) 0.12 [0.04-0.66] 8.8 [4.0, 40]N10
27
A156T 1a,1b 1 .62(H) 7 0.14 (0.09) 0.06 [0.04-6.57] 1.4 [1.2, 1.6]N10
24
A156V 1b 1 .62(H) 5 0.10 (0.08) 0.04 [0.00-5.88] 1.3 [1.2, 1.5]N10
24
V36M/T54S 1a 2 ND
h (H) 2 0.31 (0.20) 0.40 [0.18-0.61] 4.1 [n.a., n.a.]N10
27
aOnly variants detected for more than one subject are shown.
bNumber of subjects from whose data variant fitness was estimated.
cIC50 values were measured in replicon cells; (L) variant with low-level resistance; (H) variant with high-level resistance.
dMean and standard deviation (SD) computed among subjects.
eThe precision of the fitness estimates, standard deviation (SD) of the estimation error in the point estimates of optimal parameter values, was calculated for each
subject. The median and range was reported among subjects. N.a. not available (because the optimal value is at lower bound).
f95% confidence intervals were computed only for variants whose fitness was estimated from more than 5 subjects.
gIn the estimation, the IC50 of T54S was assumed to be the same as that of T54A.
hIn the estimation, the IC50 of V36M/T54S was assumed to be the same as that of V36M/R155K.
doi:10.1371/journal.pcbi.1000745.t002
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s produced similar objective values, suggesting robustness of the
model fits to the s values in the range examined. The estimated s
values (Figure 5b) had a logarithmic median of 10
20.88 h
21,a
value comparable to the regeneration rate of liver tissues (10
20.3–
10
20.6 h
21) [34]. The optimal estimates of R0,WT varied with s,
with median (range) log10 values of 1.66 (0.93, 3.43) and 1.49
(0.85, 3.43) for estimated s and fixed s cases respectively, and
higher s correlated to lower estimates of R0,WT (Figure 5c).
However, the estimates of the production rate ratio fi were more
robust to the s values (Figure 5d–f).
Sensitivity to different mutation rates
In the base runs, the mutation rates were assumed to be random
with no effect of evolutionary selection, using a value reported
from data including evolutionary selection [26]. The inclusion of
evolutionary selection may result in mutation rates that underes-
timated actual rates. Because of this difference in the inclusion of
selection to the assumed base mutation rate, we further examined
the sensitivity of the estimation results to the assumed rates by
repeating the estimations with 10-fold lower, 10-fold and 100-fold
higher rates. The results were provided in Figure 6. The objective
function values were the lowest for the base case with m of
1.2610
24 changes/site/cycle, suggesting that this rate produced
the best correspondence between data and model. The ranking of
estimated fitness fi was qualitatively similar in the three lowest m
values explored, suggesting that the fitness estimates were robust to
the assumption of m values in the range of [1.2610
25, 1.2610
23]
changes/site/cycle (fi for the highest m were not reported because
of poor model fits). The fitness estimates of the double mutant
variants (V36M/R155K, V36M/T54S) were affected the most by
m; lower m produced higher estimates of production rate ratio f for
these variants. This relationship could be explained by the fact that
lower m corresponded to lower pre-dosing levels of these double
mutants, and to correspond to the levels measured at Day 14, the
estimation converged to faster estimates of replication rates (or
higher f values) of these mutants.
Rationale for the on-dosing increase in infected-cell
clearance d
One feature distinguishing the model proposed here from that
previously proposed in HIV [19] is the increase of infected-cell
clearance d as a function of on-dosing blockage, given by Equation
5. The higher d was motivated by the observation that WT d values
were up to 10-times higher in subjects dosed with telaprevir than in
subjects treated with Peg-IFN/RBV [24]. This second-phase
decline is much more rapid than the 0.2-fold increase in the decline
predicted by increased telaprevir blockage alone, a lower bound
value calculated when T is held constant (similar differences in the
estimates were also obtained when T was allowed to vary [24]). On
theotherhand,inthe limitofnotelaprevir,dishouldconvergetod0.
These two limits constrain alternative relationships between d and
on-dosing blockage. For the base case, we chose a model in which di
decreases linearly with log10(1-ei) as given in Equation 5.
Figure 2. Correspondence between in vitro replicative fitness and in vivo fitness computed using two alternative methods. Panel a,
in vivo fitness computed using modeling proposed here. Panel b, in vivo fitness computed using the Relative Fitness method. The in vitro fitness was
measured in replicon cells and has been reported in [16,17]. When compared to fitness estimates in vitro, in vivo fitness estimates from modeling
correspond better than the estimates from the Relative Fitness method. Relative Fitness was computed as the ratio of rate of change of viral loads (in
log-scale) between a variant and wild-type (see methods).
doi:10.1371/journal.pcbi.1000745.g002
Table 3. Fitness estimates using relative fitness and
production rate ratio (f) in Subject 2.
V36A (vs. WT) Values
RFD14 vD21 0.337
RFD21vD150 20.101
f 0.578
Model-derived RFDay15 20.671
Model-derived RFDay100 20.023
Relative Fitness (RF) was calculated from data as the ratio (of a variant and wild-
type) of the rate of change of viral loads (in log scale). Model-derived RF was
calculated similarly, with the rate of change of viral loads from time-derivative
of the simulated viral loads at a specified time (see methods).
doi:10.1371/journal.pcbi.1000745.t003
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the correspondence between data and model fits with and without
d enhancement. The model with d enhancement (ddrug estimated,
dnodrug was assumed to be the same as that from Peg-IFN/RBV
treatments, and was fixed to the mean value of 0.005 h
21) was
compared to that without d enhancement (ddrug=0, dnodrug
estimated); both models have the same number of estimated
parameters. The results are shown in Figure 7. Figure 7a shows the
objective values for both models. With the same degree of freedom
in both models, the model with d enhancement tends to have
lower objective values than that without d enhancement,
suggesting better correspondence of the d enhancement model
to the data. Figure 7b and c show the example of the
correspondence of model without enhancement applied to Subject
1. The model without enhancement missed the much more rapid
on-dosing HCV RNA declines while maintaining the fit to variant
prevalence data. These observations suggest that d enhancement
affects both WT and variants.
To represent the d enhancement in WT and variants, while
satisfying the two limits of the observed second slope described
above, we also examined alternative equations to Equation 5. In
particular, we examined models with di as a linear function of (1-ei)
(Equation 6) and models with di as a step-function to the presence
of telaprevir (Equation 7). Because the number of parameters
estimated in each patient are the same, one may compare the
objective functions directly to represent the goodness of fit. The
results are provided in Figure 8. Compared to the base model with
Equation 5, the model including Equation 6 produced similar
quality of fit. However, the model with Equation 7 produced
inferior fits. These suggest that the increase in the second slope is
blockage-dependent.
Relative contribution of factors leading to an initial
decline of variants levels on dosing
Upon dosing with telaprevir, variants’ RNA levels were
predicted to decline initially because of two factors: blockage of
Figure 3. Perturbation analysis of Subject 1, had resistant variants not pre-existed prior to dosing. The simulation was initialized with
resistant variants not pre-existed at 0.4 d before dosing; the duration of 0.4 d was chosen as the minimum duration for the plasma HCV RNA of
variants to reach steady-state by time=0. Legends: diamonds, data; lines, models with no variants present at 0.4 day before dosing. Had variants not
pre-existed prior to dosing, HCV RNA rebound is expected to occur at later time.
doi:10.1371/journal.pcbi.1000745.g003
Figure 4. Comparison between data and best-fit models for alternative cases of replication space T dynamics applied to Subject 1.
Panel a, comparison for plasma HCV RNA. Panel b, comparison for variant prevalence composition. Legends: black lines, overall HCV RNA load; grey
lines, fraction of available replication space T/Tmax; colored lines, contribution of variants to HCV RNA load; solid lines, T followed Equation 1 and s was
optimally estimated at 0.03 h
21; dashed lines, T followed Equation 1 and s was fixed at 1 h
21; dotted lines, T followed Equation 8 and c was fixed at
0.05 h
21 — a value comparable to s=1h
21 in Equation 1. Alternative representations of similar rate of increase in replication space T provide
qualitatively similar fits to data.
doi:10.1371/journal.pcbi.1000745.g004
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due to rapid WT clearance. To examine the relative contributions
of these two factors, the model components were examined at the
beginning of dosing. At this timepoint, the reduction of variant i’s
replication flux by telaprevir blockage can be approximated as -ei fi
Ii, and the reduction of influx mutation by WT clearance can be
approximated as mWT,i fWT IWT. Thus, assuming that prior to
dosing Vi/VWT = mWT,i/(1-fi), the ratio of reduced replication of
variant i by blockage to that by mutation can be approximated by
ei fi/(1-fi). If we assumed an effective telaprevir concentration
[TVR] of 4 mM (the average [TVR] in the cohorts studied here)
and calculated e from Equation 5, then for the V36M variant with
intermediate susceptibility (IC50=4.73 mM, Hill coefficient
h=3.5, fV36M=0.68), this ratio was 0.97. For the A156T variant
with high resistance and low fitness (IC50 =10
3 mM, h=1,
fA156T=0.1), the ratio was 4610
24. For the V36M/R155K
variant with high resistance and high fitness (IC50=142 mM,
h=3.5, fV36M/R155K=0.5), this ratio is 4610
26. The fact that
these ratios are all ,1 suggests that the reduction in influx
mutations from WT, rather than the increased telaprevir blockage,
dominated the initial reduction of the variants’ replication rates.
Discussion
The HCV viral dynamics in subjects dosed with telaprevir were
representedbyamulti-variantmodelthatincludedthe heterogeneity
of variants’ fitness, and resistant profiles in the HCV quasispecies.
During telaprevir dosing, the overall viral load initially declined as
WT was inhibited and replication space available to variants
increased, allowing pre-existing variants with sufficient on-dosing
fitness to emerge. Unlike during HIV infection, where replication
space can be quantified by measuring healthy CD4+ cells [35]
replication space in HCV-infected subjects cannot be measured
directly. However, the concept of limited replication space is
important in HCV infection because HCV RNA levels reach a
steady-state value in chronically infected subjects, indicating limited
resources for viral replication. Biologically, the replication space in
HCV may be limited by the number of healthy hepatocytes, or by
other factors necessary for viral replication within these cells (e.g.,
factors for RNA and/or protein synthesis, or for inhibition of the
double-stranded RNA induced signaling pathway [36]).
The increase in replication space and the on-dosing fitness of
variants were the primary determinants of HCV RNA rebound
Figure 5. The roles of replication space (T) kinetics to model estimates. Two cases of T dynamics were examined: first, T synthesis rate s was
estimated (range: [0.01–1] h
21) simultaneously with other parameters; second, s was fixed to 1 h
21. Panel a, Maximum likelihood objective function
values for both cases. Majority of values are within the objective function differences expected from likelihood ratio for one additional parameter
estimated. Panel b, Boxplot of synthesis s values. Panel c, Boxplot of log10 of reproductive ratio. Estimates of reproductive ratio is lower when s is
higher (when s was fixed to its upper bound of 1 h
21). Panel d, Fitness fi for both cases. Similar values suggests robustness to assumed synthesis rate
s in both cases. Panels e–f, Boxplot of fitness f values of two representative variants T54A and A156T for both cases.
doi:10.1371/journal.pcbi.1000745.g005
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mutations during treatment. The finding of variants prior to
dosing [12,13] and within a week on-treatment in other studies
[15] suggested that the variants contributing to virologic rebound
in the present study were likely to pre-exist. The pre-existence of
variants is supported by the modeling results; had they not pre-
existed, calculations based on the HCV mutation rate, replication
rate, and HCV RNA level at baseline indicated that rebound
would have been delayed. A complementary computational
analysis of HIV viral dynamics has also identified the likelihood
of some HIV variants pre-existing [37]. The mechanism of viral
rebound (by resistant variants when WT is cleared) is also
Figure 6. Estimation results for different values of mutation rates m. Panel a, maximum likelihood objective values for mutation rates m of
1.2610
25/cycle, 1.2610
24/cycle, 1.2610
23/cycle, and 1.2610
22/cycle. The objective functions are the lowest with m=1.2610
24/cycle, suggesting
models fit data best with this m value. Panel b, estimated fitness of selected variants at different m values. Similar ranking of fitness estimates were
obtained with these different values of mutation rates. Similar fitness estimates suggests robustness to the assumed mutation rate m. Fitness
estimates for m=1.2610
22/cycle were not reported because of poor model fits.
doi:10.1371/journal.pcbi.1000745.g006
Figure 7. Comparison of cases with (ddrug?0) and without (ddrug=0) telaprevir-enhanced infected-cell clearance rate constants. In
ddrug?0, ddrug was estimated from data while dnodrug was fixed at the average value for Peg-IFN/RBV treatment (5.2610
23 h
21); in ddrug=0 case,
dnodrug was estimated from data while ddrug was fixed at zero. Panel a, objective values for both cases. The values with ddrug=0 were higher than
those with nonzero ddrug, suggesting better correspondence of data and model fit with ddrug?0. The number of parameters estimated in both cases
is the same. Panels b and c, correspondence between plasma HCV RNA (b) and variant prevalence (c) data and best-fit models for Subject 1.
Legends: solid lines, best-fit models with ddrug=0 case; dotted lines, best-fit models with ddrug?0 case; dashed lines, variant HCV RNA predicted by
best-fit models with ddrug=0 case. Without ddrug, the best-fit model must trade-off the fitting error on during-dosing second phase decline to match
prolonged variants persistence at post-dosing.
doi:10.1371/journal.pcbi.1000745.g007
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[38,39]. Moreover, rapid virologic rebound in HIV-infected
subjects treated with nonnucleoside reverse transcriptase inhibitors
[40,41] has also been attributed to the pre-existence of variants
[42]. A caveat here is that the risk of other (novel) resistant variants
being generated on-treatment is higher if HCV is not cleared
rapidly. Higher HCV RNA levels translate to more replication
cycles and thus, larger risk of developing new variants. The higher
risk further highlights the importance of treating HCV-infected
subjects with potent regimens.
Based on data observed during the emergence of telaprevir
resistant variants, the model described herein estimates a
replication space synthesis rate s in subjects chronically infected
with HCV that is higher than the s obtained for subjects
chronically infected with HIV [19], and estimated reproductive
ratio R0 values that were both higher and more variable
compared to those for HIV. The high s is consistent with the
high regenerative rates of hepatocytes [34]. Additionally, this
high s may reflect the additional influx of healthy cells as a result
of HCV RNA elimination in infected-cells (cured cells),
consistent with the observed faster second-phase decline in
subjects with HCV dosed with telaprevir as compared to the
decline in subjects treated with IFN/RBV [24]. The R0 values
for HCV estimated here were about 2-fold higher (median: 45.7;
range: 8.51 to 2692) than the values obtained from acute HIV
infections (Number of patient N=5, median: 19.3, range: 7.4 to
34) [43], and about 11-fold higher than the values after
interruption of antiretroviral therapy [43]. Because HCV
infected-cell clearance rates---a component of R0---may be
affected by innate immunity, it is plausible that the higher
variability of R0 for HCV may be related to the HCV
interference of the innate immunity [44,45].
All variants resistant to telaprevir estimated here have reduced
replicative fitness in vivo compared to WT in the absence of
telaprevir. The phenotypic and structural bases for the resistance
and reduced fitness of these variants have been discussed elsewhere
[16,17]. The reduced fitness is consistent with 98% of HCV-
infected subjects having quasispecies dominated by WT prior to
dosing [46] and with the finding that after telaprevir dosing was
stopped, WT regained its dominance in the quasispecies [14,15].
Resistant HIV variants also have reduced fitness [47,48,49].
However, in contrast to treatments in HIV, treatments in HCV
may result in a sustained viral response (clearance of virus).
Variants resistant to telaprevir remain sensitive to Peg-IFN/RBV
in vitro [16,17], and their reduced fitness may reduce the ‘‘load’’ for
Peg-IFN/RBV treatment within a subject, increasing the percent-
age of HCV-infected subjects responding to Peg-IFN/RBV
treatment. This suggests that a shorter treatment duration and/
or a higher percentage of subjects reaching SVR may potentially
be possible using triple therapy with telaprevir, Peg-IFN and RBV
than with Peg-IFN and RBV alone.
Models with on-dosing increase of infected cell clearance
provided better fits of the data. Estimates of second slopes of
HCV RNA decline during the first three days of dosing
attributable to WT HCV dynamics revealed 10-fold increased
infected-cell clearance compared to treatment with interferon and
ribavirin [24]. Here, we also found that, when compared to
models with enhanced infected-cell clearance, models lacking the
enhanced clearance are inferior in estimating data. Moreover, we
found that models that includes a blockage-dependent second
slope fit the data better than models with a switch-like second
slope. Biologically, we hypothesized that the phenomenon may be
related to the interference of HCV in the innate immune response
[44,45]. Elimination of WT HCV by telaprevir may allow
previously WT-dominant infected cells to restore their normal
innate immune response while variant levels are low, resulting in a
more rapid second-phase decline.
The HCV RNA response in subjects dosed with telaprevir
monotherapy and the estimate of variants’ fitness have been
quantified using a multi-variant viral dynamic model. Here we
showed how diversity in viral quasispecies should be accounted for
in a model of antiviral response to specifically-targeted antiviral
compounds.
Supporting Information
Text S1 Supplementary text
Found at: doi:10.1371/journal.pcbi.1000745.s001 (0.06 MB
DOC)
Figure 8. Objective values for alternative equations representing enhanced infected-cell clearance rates d (Equations 5, 6, and 7).
Each of the models have the same number of parameters estimated for each subject. Models with di that depend on blockage e (Equations 5 and 6)
have similar quality of fits. However, the model without dependency to e (Equation 7) has inferior quality of fits.
doi:10.1371/journal.pcbi.1000745.g008
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Found at: doi:10.1371/journal.pcbi.1000745.s002 (0.06 MB
DOC)
Table S2 Type of variants with fitness estimates for each subject.
Four variants were observed only in one subject and are not
included. Nsubjects, the number of subjects in which the variant
was observed; Nvariants, the number of variants observed within a
subject.
Found at: doi:10.1371/journal.pcbi.1000745.s003 (0.12 MB
DOC)
Table S3 Variants susceptibility to telaprevir as measured in
replicon cells
Found at: doi:10.1371/journal.pcbi.1000745.s004 (0.05 MB
DOC)
Table S4 Bounds on the estimated parameters
Found at: doi:10.1371/journal.pcbi.1000745.s005 (0.05 MB
DOC)
Figure S1 Correspondence between data and model estimation
in three additional subjects. a, Subject 2 HCV RNA levels; b,
Subject 2 variant prevalence; c, Subject 3 HCV RNA levels; d,
Subject 3 variant prevalence level; e, Subject 4 HCV RNA levels;
f, Subject 4 prevalence. Diamonds, data; solid line, best-fit model;
dashed lines, predicted variant contribution to the overall plasma
HCV RNA; circles, HCV RNA levels of variants (limited to
variants with prevalence .5%).
Found at: doi:10.1371/journal.pcbi.1000745.s006 (1.80 MB EPS)
Figure S2 Sensitivity of estimation results to assumption of b
values applied to data from Subject 1. Panel A, Maximum
likelihood objective values. The objective values were similar
despite large variations of fixed pre-estimated b. Panel B,
estimated production rate constant p for a given b value.
Production rate p is related to 1/b. Panel C, estimated fitness of
V36M. Panel D, estimated fitness of R155K. Estimated fitness
converged to similar values despite large variations of assumed b
values. The estimation was repeated 2000 times for this subject
with different b values (with b/b0=10
brandom; brandom as a
random variable with mean=0, std=1). Initial seed and bounds
for p were adjusted to maintain constant (pbTmax/(cd)) values (p/
p0=10
(-brandom);p 0 as the estimated p when b=b0). The same
estimates of reproductive ratio R0 and fitness fi were obtained
despite extreme ranges of b.
Found at: doi:10.1371/journal.pcbi.1000745.s007 (2.09 MB EPS)
Figure S3 Sensitivity to alternative models with different
representation of variant fitness: Baseline: where fitness is
represented by different production rates fi p; Case 1, where
fitness is represented by different infection rate fi b; Case 2, where
fitness is represented by different plasma clearance rate c/fi. These
alternative models maintain the same variant reproductive ratio
R0,i and resulted in similar viral dynamics.
Found at: doi:10.1371/journal.pcbi.1000745.s008 (0.09 MB TIF)
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